A detailed history of Aveo Capital Partners, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Aveo Capital Partners, LLC holds 1,667 shares of LLY stock, worth $1.52 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
1,667
Previous 2,006 16.9%
Holding current value
$1.52 Million
Previous $1.56 Million 3.27%
% of portfolio
0.18%
Previous 0.18%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

SELL
$724.87 - $909.04 $245,730 - $308,164
-339 Reduced 16.9%
1,667 $1.51 Million
Q1 2024

May 06, 2024

SELL
$592.2 - $792.28 $8,290 - $11,091
-14 Reduced 0.69%
2,006 $1.56 Million
Q4 2023

Feb 06, 2024

BUY
$525.19 - $619.13 $80,354 - $94,726
153 Added 8.19%
2,020 $1.18 Million
Q3 2023

Nov 06, 2023

SELL
$434.7 - $599.3 $147,363 - $203,162
-339 Reduced 15.37%
1,867 $1 Million
Q2 2023

Aug 08, 2023

BUY
$350.74 - $468.98 $51,909 - $69,409
148 Added 7.19%
2,206 $1.03 Million
Q1 2023

May 03, 2023

SELL
$310.63 - $364.82 $28,267 - $33,198
-91 Reduced 4.23%
2,058 $706,000
Q4 2022

Feb 03, 2023

BUY
$321.55 - $374.67 $19,614 - $22,854
61 Added 2.92%
2,149 $786,000
Q3 2022

Nov 09, 2022

BUY
$296.48 - $337.87 $3,261 - $3,716
11 Added 0.53%
2,088 $675,000
Q2 2022

Aug 05, 2022

SELL
$278.73 - $327.27 $7,246 - $8,509
-26 Reduced 1.24%
2,077 $673,000
Q1 2022

May 13, 2022

BUY
$234.69 - $291.66 $2,346 - $2,916
10 Added 0.48%
2,103 $602,000
Q4 2021

Feb 11, 2022

SELL
$224.85 - $279.04 $6,070 - $7,534
-27 Reduced 1.27%
2,093 $578,000
Q3 2021

Nov 12, 2021

SELL
$221.6 - $272.71 $7,091 - $8,726
-32 Reduced 1.49%
2,120 $490,000
Q2 2021

Aug 13, 2021

SELL
$180.55 - $233.54 $2,708 - $3,503
-15 Reduced 0.69%
2,152 $494,000
Q1 2021

May 11, 2021

BUY
$164.32 - $212.72 $356,081 - $460,964
2,167 New
2,167 $405,000
Q4 2020

Feb 10, 2021

SELL
$130.46 - $172.63 $293,535 - $388,417
-2,250 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$146.22 - $169.13 $328,995 - $380,542
2,250 New
2,250 $333,000
Q2 2020

Aug 12, 2020

SELL
$136.42 - $164.18 $292,893 - $352,494
-2,147 Closed
0 $0
Q1 2020

May 05, 2020

SELL
$119.05 - $147.35 $32,976 - $40,815
-277 Reduced 11.43%
2,147 $298,000
Q4 2019

Feb 06, 2020

BUY
$106.92 - $132.43 $4,704 - $5,826
44 Added 1.85%
2,424 $319,000
Q3 2019

Nov 07, 2019

SELL
$106.79 - $116.16 $1,708 - $1,858
-16 Reduced 0.67%
2,380 $269,000
Q2 2019

Aug 06, 2019

BUY
$110.79 - $129.32 $5,428 - $6,336
49 Added 2.09%
2,396 $260,000
Q1 2019

May 07, 2019

BUY
$111.31 - $131.02 $29,608 - $34,851
266 Added 12.78%
2,347 $305,000
Q4 2018

Feb 11, 2019

SELL
$105.9 - $118.64 $6,459 - $7,237
-61 Reduced 2.85%
2,081 $241,000
Q3 2018

Nov 09, 2018

BUY
$85.86 - $107.31 $183,912 - $229,858
2,142 New
2,142 $240,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $864B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Aveo Capital Partners, LLC Portfolio

Follow Aveo Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aveo Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aveo Capital Partners, LLC with notifications on news.